J3387 HCPCS Level II code: Injection, elivaldogene autotemcel, per treatment
J3387 is the HCPCS code for “Injection, elivaldogene autotemcel, per treatment” in CMS’s October 2026 release, in effect from Oct 1, 2026.
Official description
J3387Injection, elivaldogene autotemcel, per treatment
Short description: Inj elivaldogene autotemecel
HCPCS · United States
Medicare details
The indicators CMS publishes with J3387 in its October 2026 file. They describe Medicare’s handling, not another payer’s.
- Medicare coverage
- Carrier judgment
- Medicare pricing
- Drugs
- Type of service
- Medical care; Lump sum purchase of DME, prosthetics, orthotics
- BETOS category
- Other drugs
- Added
- Jan 1, 2026
Where J3387 sits
- 1J codesDrugs administered other than orally
- 2Active code J3387Injection, elivaldogene autotemcel, per treatment
Source and release
- Data release
- HCPCS Level II · October 2026
- Effective date
- Oct 1, 2026
- Publisher
- CMS
This page is built from the HCPCS Level II catalog that Vero Codes reads when it suggests codes: Centers for Medicare & Medicaid Services’s October 2026 release, imported from the publisher’s file and checked against it. The description, notes and structured data come from the same record.
Frequently asked questions
What does HCPCS code J3387 mean?
J3387 is the HCPCS code for “Injection, elivaldogene autotemcel, per treatment” in CMS’s HCPCS Level II October 2026 release.
Does Medicare cover J3387?
CMS lists J3387’s Medicare coverage as “Carrier judgment” and its pricing as “Drugs”. Coverage and payment still depend on the patient, the setting, the documentation and the payer.
Which HCPCS Level II release does this page use?
It uses CMS’s October 2026 release, in effect from Oct 1, 2026 to Dec 31, 2026. It is a reference: confirm the code against the current list and the payer’s rules before you submit it.
Codes beside J3387
All J codesJ3375Injection, vancomycin hydrochloride (tyzavan), not therapeutically equivalent to j3373, 10 mgJ3376Injection, vancomycin hcl (hikma), not therapeutically equivalent to j3373, 10 mgJ3379Injection, valproate sodium, 5 mgJ3380Injection, vedolizumab, intravenous, 1 mgJ3385Injection, velaglucerase alfa, 100 unitsJ3386Injection, etuvetidigene autotemcel, per treatmentJ3389Topical administration, prademagene zamikeracel, per treatmentJ3391Injection, atidarsagene autotemcel, per treatmentJ3392Injection, exagamglogene autotemcel, per treatmentJ3393Injection, betibeglogene autotemcel, per treatmentJ3394Injection, lovotibeglogene autotemcel, per treatmentJ3396Injection, verteporfin, 0.1 mg